Drug Analysis: Bavencio

Drug Analysis: Bavencio

  • December 2017 •
  • 64 pages •
  • Report ID: 5336330 •
  • Format: PDF
Drug Overview
Bavencio is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell activation, proliferation, and survival, and can induce apoptosis of tumor-specific T cells (Keir et al., 2008; Zhang et al., 2009; Zitvogel and Kroemer, 2012).

By inhibiting the PD-1/PD-L1 interaction, Bavencio reduces the ability of the tumor to evade immune system targeting, and enables the activation of T cells and the adaptive immune system (Avelumab fact sheet, 2015; Pardoll, 2012). In addition, preclinical and clinical studies have suggested that drugs targeting the PD-1/PD-L1 pathway may have fewer side effects than other immune checkpoint inhibitors (Raufi and Klempner, 2015; Brahmer et al., 2012).